Antihemophilic factor (recombinant) plasma/albumin-free method for the management and prevention of bleeding episodes in patients with hemophilia A.
Hemophilia is a rare genetic bleeding disorder that, if not adequately controlled, is associated with life-threatening bleeding events and serious and costly complications, primarily from joint damage. The advent of effective clotting factor replacement therapy for patients with hemophilia is considered one of the foremost medical advances of the 20th century. The last 3 decades of experience in hemophilia care have witnessed the effectiveness of the care of patients with hemophilia within specialized comprehensive care centers, advances in factor replacement therapies, the benefits of prophylaxis over on-demand replacement therapy, and the role of aggressive management of joint disease to prevent dysfunction. Ongoing challenges, including the management of inhibitors to factor therapies and the consequences of thousands of patients with hemophilia becoming infected with human immunodeficiency virus and hepatitis C virus in the 1980s from contaminated plasma-derived factor concentrates, have highlighted the need for vigilance with respect to clotting factor product safety, access to care, and a full complement of choice of factor replacement therapies. Advate((R)) (antihemophilic factor [recombinant] plasma/albumin-free method [rAHF-PFM]) is the first recombinant factor VIII therapy manufactured without human or animal protein additives to eliminate the risk of pathogen transmission that could be carried by these additives. Preclinical studies established bioequivalence with recombinant antihemophilic factor (Recombinate((R))), a product with 16 years of clinical experience. Currently licensed in 44 countries worldwide, rAHF-PFM has over 7 years of clinical research within 5 global studies supporting its safety and efficacy in the treatment of patients with hemophilia A.
Pipe
Steven
S
Department of Pediatrics and Communicable Diseases, University of Michigan, Ann Arbor, MI, USA. ummdswp@med.umich.edu
Pediatrics. 2001 Dec;108(6):E105
11731632
Transfusion. 2004 Aug;44(8):1179-85
15265122
J Intern Med. 1992 Jul;232(1):25-32
1640190
Haemophilia. 2004 Mar;10 Suppl 1:63-70
14987251
Blood. 2000 Jul 15;96(2):437-42
10887103
Haemophilia. 2003 Jan;9(1):1-23
12558775
Thromb Haemost. 2008 May;99(5):840-50
18449413
Haemophilia. 1999 Nov;5(6):378-85
10583523
Blood. 2007 Jun 1;109(11):4648-54
17289808
Thromb Haemost. 1997 Apr;77(4):660-7
9134639
Thromb Haemost. 1996 Dec;76(6):1120
8972042
Thromb Res. 2002 Mar 1;105(5):391-400
12062540
N Engl J Med. 2007 Aug 9;357(6):535-44
17687129
Haemophilia. 2005 Nov;11(6):589-97
16236108
Soc Sci Med. 2001 Oct;53(8):1081-94
11556777
Haemophilia. 2000 Jan;6(1):23-32
10632738
Haemophilia. 2003 Jan;9(1):38-49
12558777
MMWR Suppl. 1987 Dec 18;36(6):1-48
3123906
Lancet. 2004 Aug 7-13;364(9433):527-9
15302196
Haemophilia. 2005 Nov;11(6):571-82
16236106
Thromb Haemost. 2008 Aug;100(2):217-23
18690340
Am J Hematol. 1998 Dec;59(4):288-94
9840909
Thromb Haemost. 1999 Mar;81(3):476-7
10102490
Bull World Health Organ. 1995;73(5):691-701
8846496
Br J Haematol. 2009 Jan;144(1):14-23
18950452
Semin Hematol. 2004 Jan;41(1 Suppl 2):1-16; discussion 16-8
15071785
Euro Surveill. 2005 Feb;10(2):17-9
15735312
Semin Hematol. 2006 Apr;43(2 Suppl 3):S23-7
16631824
Blood. 1994 May 1;83(9):2428-35
8167332
Thromb Haemost. 2001 Mar;85(3):560
11307831
MMWR Morb Mortal Wkly Rep. 1982 Jul 16;31(27):365-7
6815443
Haemophilia. 2003 May;9 Suppl 1:10-7; discussion 18
12709032
Haemophilia. 2002 Jan;8(1):44-50
11886464
Haemophilia. 2003 May;9(3):272-8
12694517
N Engl J Med. 2003 Sep 25;349(13):1236-45
14500806
Haemophilia. 2004 Sep;10(5):428-37
15357767
Artif Cells Blood Substit Immobil Biotechnol. 2000 Sep;28(5):375-83
11009110
Thromb Haemost. 2000 Jun;83(6):811-6
10896230
J Thromb Haemost. 2008 Aug;6(8):1319-26
18503631
Lancet. 2004 Feb 7;363(9407):417-21
14962520
Am J Hematol. 2001 Apr;66(4):229-40
11279632
Vasc Health Risk Manag. 2007;3(5):555-65
18078007
J Neurol Neurosurg Psychiatry. 2004 Mar;75 Suppl 1:i36-42
14978149
Haemophilia. 2006 Mar;12 Suppl 1:16-20; discussion 26-8
16445813
Lancet. 2004 Aug 7-13;364(9433):477-9
15302172
Thromb Haemost. 2005 Mar;93(3):457-67
15735795
Transfusion. 2001 Mar;41(3):338-43
11274587